PSG3 and cancer: We then asked if this pattern (a statistically significant alteration of the ‘KRAS Signaling Down’ pathway between the PSG+ and PSG− groups in female LUAD patients grouped by the signature of PSG3, PSG7, and PSG8) is present in other TCGA cancer datasets.